Comera Life Sciences Holdings, Inc.
Simbols: CMRA
NASDAQ
0.02684
USDTirgus cena šodien
-0.0074
P/E koeficients
0.0000
PEG koeficients
1.17M
MRK Cap
- 0.00%
DIV ienesīgums
Comera Life Sciences Holdings, Inc. (CMRA) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | |||
---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 4.23 | 0.4 | 6.5 | 0.2 | |||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||
balance-sheet.row.net-receivables | 0.63 | 0 | 0.2 | 0.1 | |||
balance-sheet.row.inventory | 3.98 | 2.5 | 0 | 0 | |||
balance-sheet.row.other-current-assets | 1.08 | 0.1 | 0 | 0 | |||
balance-sheet.row.total-current-assets | 9.93 | 3.1 | 6.8 | 0.3 | |||
balance-sheet.row.property-plant-equipment-net | 1.84 | 0.6 | 0.6 | 0.2 | |||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||
balance-sheet.row.other-non-current-assets | 0.37 | 0.1 | 0.1 | 0.1 | |||
balance-sheet.row.total-non-current-assets | 2.21 | 0.7 | 0.6 | 0.2 | |||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||
balance-sheet.row.total-assets | 12.14 | 3.7 | 7.4 | 0.5 | |||
balance-sheet.row.account-payables | 6.53 | 1.5 | 0.4 | 0.1 | |||
balance-sheet.row.short-term-debt | 1.85 | 0.7 | 0.1 | 0.1 | |||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||
balance-sheet.row.long-term-debt-total | 0.17 | 0.1 | 0.2 | 0.2 | |||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||
balance-sheet.row.other-current-liab | 5.52 | 2.8 | 0 | 0 | |||
balance-sheet.row.total-non-current-liabilities | 18.92 | 4.9 | 21.1 | 0.2 | |||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||
balance-sheet.row.capital-lease-obligations | 0.98 | 0.3 | 0.3 | 0 | |||
balance-sheet.row.total-liab | 34.22 | 10 | 22.1 | 0.4 | |||
balance-sheet.row.preferred-stock | 13622.31 | 4517.7 | 20.9 | 0 | |||
balance-sheet.row.common-stock | 0.01 | 0 | 0 | 10.7 | |||
balance-sheet.row.retained-earnings | -152.04 | -34.9 | -16.9 | -11.4 | |||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -9017.78 | 0 | -20.9 | 0 | |||
balance-sheet.row.other-total-stockholders-equity | -4474.58 | -4489.1 | 2.2 | 0.9 | |||
balance-sheet.row.total-stockholders-equity | -22.08 | -6.2 | -14.7 | 0.2 | |||
balance-sheet.row.total-liabilities-and-stockholders-equity | 12.14 | 3.7 | 7.4 | 0.5 | |||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||
balance-sheet.row.total-equity | -22.08 | -6.2 | -14.7 | 0.2 | |||
balance-sheet.row.total-liabilities-and-total-equity | 12.14 | - | - | - | |||
Total Investments | 0 | 0 | 0 | 0 | |||
balance-sheet.row.total-debt | 2.02 | 0.8 | 0.3 | 0.2 | |||
balance-sheet.row.net-debt | -2.2 | 0.3 | -6.2 | 0 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | |||
---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -9.01 | -18 | -5.5 | -2.1 | |||
cash-flows.row.depreciation-and-amortization | 0.1 | 0.1 | 0.1 | 0.1 | |||
cash-flows.row.deferred-income-tax | -0.08 | 0 | -0.2 | 0 | |||
cash-flows.row.stock-based-compensation | 1 | 0.4 | 1.1 | 0.1 | |||
cash-flows.row.change-in-working-capital | 1.41 | 2.6 | 0.6 | 0 | |||
cash-flows.row.account-receivables | 0.29 | 0 | 0.1 | -0.1 | |||
cash-flows.row.inventory | 0.51 | 0 | 0.2 | 0.1 | |||
cash-flows.row.account-payables | -0.4 | 0.9 | 0.3 | 0 | |||
cash-flows.row.other-working-capital | 1 | 1.7 | 0 | 0 | |||
cash-flows.row.other-non-cash-items | -0.08 | 5.2 | 0.1 | 0.2 | |||
cash-flows.row.net-cash-provided-by-operating-activities | -6.66 | 0 | 0 | 0 | |||
cash-flows.row.investments-in-property-plant-an-equipment | -28.68 | 0 | -0.1 | 0 | |||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | |||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||
cash-flows.row.other-investing-activites | 0.01 | 0 | 0 | 0 | |||
cash-flows.row.net-cash-used-for-investing-activites | -28.66 | 0 | -0.1 | 0 | |||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | |||
cash-flows.row.common-stock-issued | 0.13 | 0.8 | 0 | 1.4 | |||
cash-flows.row.common-stock-repurchased | 650 | 650 | 0 | 0 | |||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||
cash-flows.row.other-financing-activites | -644.28 | -645.6 | 10.3 | 0.2 | |||
cash-flows.row.net-cash-used-provided-by-financing-activities | 5.85 | 5.2 | 10.3 | 1.6 | |||
cash-flows.row.effect-of-forex-changes-on-cash | 28.57 | 0 | 0 | 0 | |||
cash-flows.row.net-change-in-cash | -0.9 | -4.6 | 6.4 | -0.3 | |||
cash-flows.row.cash-at-end-of-period | 5.94 | 2 | 6.6 | 0.2 | |||
cash-flows.row.cash-at-beginning-of-period | 6.84 | 6.6 | 0.2 | 0.4 | |||
cash-flows.row.operating-cash-flow | -6.66 | -9.8 | -3.8 | -1.8 | |||
cash-flows.row.capital-expenditure | -28.68 | 0 | -0.1 | 0 | |||
cash-flows.row.free-cash-flow | -35.34 | -9.8 | -3.9 | -1.8 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | |||
---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 1 | 0.6 | 0.3 | 0.4 | |||
income-statement-row.row.cost-of-revenue | 0.26 | 0.2 | 0.2 | 0.1 | |||
income-statement-row.row.gross-profit | 0.74 | 0.4 | 0.2 | 0.3 | |||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||
income-statement-row.row.research-development | 1.43 | - | - | - | |||
income-statement-row.row.selling-general-administrative | 8.45 | - | - | - | |||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||
income-statement-row.row.other-expenses | 0 | -1.5 | -0.1 | 0 | |||
income-statement-row.row.operating-expenses | 9.88 | 12.4 | 5.7 | 2.5 | |||
income-statement-row.row.cost-and-expenses | 10.15 | 12.6 | 5.9 | 2.6 | |||
income-statement-row.row.interest-income | 0.03 | 0 | 0 | 0 | |||
income-statement-row.row.interest-expense | 0.03 | 0 | 0 | 0 | |||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||
income-statement-row.row.total-other-income-expensenet | 0.15 | -6 | 0.1 | 0 | |||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||
income-statement-row.row.other-operating-expenses | 0 | -1.5 | -0.1 | 0 | |||
income-statement-row.row.total-operating-expenses | 0.15 | -6 | 0.1 | 0 | |||
income-statement-row.row.interest-expense | 0.03 | 0 | 0 | 0 | |||
income-statement-row.row.depreciation-and-amortization | 0.1 | -1.4 | -0.1 | 0.1 | |||
income-statement-row.row.ebitda-caps | -9.07 | - | - | - | |||
income-statement-row.row.operating-income | -9.15 | -12 | -5.5 | -2.1 | |||
income-statement-row.row.income-before-tax | -9.01 | -18 | -5.5 | -2.1 | |||
income-statement-row.row.income-tax-expense | 75.23 | 6 | -0.2 | 0 | |||
income-statement-row.row.net-income | -84.25 | -24 | -5.3 | -2.1 |
Biežāk uzdotie jautājumi
Kas ir Comera Life Sciences Holdings, Inc. (CMRA) kopējie aktīvi?
Comera Life Sciences Holdings, Inc. (CMRA) kopējie aktīvi ir 3727113.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir 451365.000.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.735.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir -1.529.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir -84.219.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir -9.143.
Kāda ir Comera Life Sciences Holdings, Inc. (CMRA) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir -24038181.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 775048.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 12392727.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 1767870.000.